Gilead Sciences, Inc was Xilio Therapeutics’s largest revenue line in fiscal 2025, bringing in $23.60M of $43.70M (54%).
| Counterparty Name | FY 2024 | FY 2025 |
|---|---|---|
| Abbvie | — | $20.10M |
| Gilead Sciences, Inc | $6.30M | $23.60M |
| Total | $6.30M | $43.70M |
Xilio Therapeutics brought in $43.70M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Xilio Therapeutics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $6.30M. Gilead Sciences, Inc was the largest at $23.60M (54.0%), ahead of Abbvie at $20.10M (46.0%).
Xilio Therapeutics began breaking out Abbvie in fiscal 2025, when it brought in $20.10M.
License & Stock Purchase Agreement was Xilio Therapeutics’s largest revenue line in fiscal 2025, bringing in $23.60M of $43.70M (54%).
| Type Of Arrangement | FY 2024 | FY 2025 |
|---|---|---|
| Collaboration & Stock Purchase Agreement | — | $20.10M |
| License & Stock Purchase Agreement | $6.30M | $23.60M |
| Total | $6.30M | $43.70M |
Xilio Therapeutics brought in $43.70M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Xilio Therapeutics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $6.30M. License & Stock Purchase Agreement was the largest at $23.60M (54.0%), ahead of Collaboration & Stock Purchase Agreement at $20.10M (46.0%).
Xilio Therapeutics began breaking out Collaboration & Stock Purchase Agreement in fiscal 2025, when it brought in $20.10M.
Xilio Therapeutics (XLO) reports its revenue by counterparty name and by type of arrangement. In fiscal 2025, Gilead Sciences, Inc was its largest revenue line, bringing in $23.60M (54.0% of the total), followed by Abbvie at $20.10M (46.0%).
Gilead Sciences, Inc was Xilio Therapeutics' largest revenue line in fiscal 2025, bringing in $23.60M, or 54.0% of the $43.70M total across its two revenue lines.
Every figure comes from Xilio Therapeutics' annual financial filings, as reported. Each line keeps the name Xilio Therapeutics gives it, and years follow its fiscal calendar.
Xilio Therapeutics' revenue by counterparty name goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.